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To estimate the effect of the introduction of the 7- and 
10-valentpneumococcal vaccines in 2006 and 2011, 
respectively in the Netherlands, we assessed respira-
tory antibiotic use in one to nine year-old children 
between 2002 and 2013. Seasonal autoregressive inte-
grated moving-average models were applied to esti-
mate the percentage reduction in respiratory antibiotic 
use. When compared with the pre-vaccination period, 
the proportion of respiratory antibiotic prescriptions 
fell by 4.94% (95% CI: 4.63 to 5.26) and 9.02% (95% 
CI: 2.83 to 14.82) after the introduction of the 7-valent 
vaccine in children aged three and four years, respec-
tively. After the introduction of the 10-valent vaccine, 
we observed a reduction of 13.04% (95% CI: 2.76 to 
22.23), 20.31% (95% CI: 13.50 to 26.58), 16.92% (95% 
CI: 3.07 to 28.80), 22.34% (95% CI: 3.73 to 37.35), 
23.75% (95% CI: 2.37 to 40.44) in two, three, four, six 
and seven year-old children, respectively. Thus, our 
results indicate a reduction in respiratory antibiotic 
prescriptions in young children after introduction of 
the pneumococcal vaccines. As only children in our 
study population aged one and two years born after 
March 2011 had received the 10-valent vaccine, the 
effects of the 10-valent vaccine in children aged three 
to nine years likely reflect the effects of the 7-valent 
vaccine and herd immunity. 
Introduction
In 2001 in the Netherlands, 45% and 20% of all anti-
biotics in children were prescribed for respiratory 
tract and ear infections, respectively, with acute otitis 
media being the leading cause [1]. One of the common 
pathogens responsible for these infections, especially 
in young children, is Streptococcus pneumoniae. In the 
United States (US), it has been found in 44% of children 
hospitalised in 1999 to 2000 with community-acquired 
lower respiratory tract infections [2]. Due to substantial 
use of antibiotics for infections caused by S. pneumo-
niae [1], preventing these infections should remain an 
important public health goal.
In June 2006, 7-valent pneumococcal vaccination was 
introduced in the Netherlands as part of the national 
Dutch immunisation programme and was provided to 
all infants free of charge [3]. Prescription rates of oral 
antibiotics for children seemed to decrease after intro-
duction of the vaccine [4], but no decline in ear, nose 
and throat problems has been observed [5]. The latter 
finding might be explained by replacement of pneu-
mococcal serotypes. Despite an overall decrease in 
invasive pneumococcal disease (IPD) after the imple-
mentation of the 7-valent vaccination campaign in the 
Netherlands, a decrease of vaccine-serotype IPD was 
followed by an increase in IPD caused by non-vaccine 
serotypes [6,7]. There has been no information, how-
ever, on any changes in use of antibiotics that are usu-
ally used for acute otitis media and pneumonia in young 
children (one to nine year-olds) in the Netherlands after 
the 7-valent pneumococcal vaccine was introduced. 
Moreover, in 2011, the 7-valent pneumococcal vaccine 
was replaced by a 10-valent vaccine [8], whose effects 
have not yet been assessed in observational studies. 
Vaccinations were provided at two, three, four months 
and a booster dose at 11 months of age, with vaccina-
tion uptake rates of 94–95% [3].
To assess the patterns of respiratory antibiotic prescrip-
tions in young children before and after the introduction 
of the pneumococcal vaccines in the Netherlands, we 
analysed the use of amoxicillin, azithromycin and sul-
famethoxazole and trimethoprim from 2002 to 2013. In 
the Netherlands, antibiotics are available by prescrip-
tion only. On the basis of Dutch general practitioner 
guidelines, these antibiotics are commonly prescribed 
for acute otitis media and pneumonia in children up to 
nine years of age in general practice [9,10]. We per-
formed descriptive and time-series analyses to assess 
whether the introduction of the pneumococcal vaccines 
nationally reduced the proportion of respiratory antibi-
otic prescriptions in children one to nine years of age.
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Methods
The study population consisted of one to nine year-old 
children identified from the IADB.nl database, which 
contains pharmacy-dispensing data from community 
pharmacies in the Netherlands. A detailed description 
of this database is available elsewhere [11]).
The main outcome of our study was the proportion of 
monthly respiratory antibiotic prescriptions in a partic-
ular age group (the number of monthly prescriptions in 
the age group per month divided by the number of chil-
dren in that age group in that month). The aggregated 
measure of respiratory antibiotic prescriptions per year 
(the number of monthly prescriptions in the age group 
per year divided by the number of children in that age 
group in that year) was calculated as well. The out-
come measure was based on prescriptions for amoxi-
cillin (Anatomical Therapeutical Chemical (ATC) code 
J01CA04), azithromycin (J01FA10) and/or sulfamethoxa-
zole and trimethoprim (ATC code J01EE01), as described 
above. The name of the antibiotic dispensed, ATC code 
[12], date of prescription and birthdate of the children 
included in the study were extracted from the IADB.nl 
database.
The first intervention studied was the introduction of 
the 7-valent pneumococcal vaccine in the Netherlands 
in June 2006 for all infants born after 1 April 2006 [3]. 
We also assessed the effects of the introduction of a 
10-valent pneumococcal vaccine for infants born after 
1 March 2011 [8].
The study period was chosen based on some pre-
liminary analyses: we excluded data before 2002 as 
we observed a decrease in respiratory antibiotic use 
between 1995 and 2002, which might have been due 
to policies and interventions targeted at decreasing 
antibiotic use, and it was not our aim to assess these 
interventions in this study. Given that, the pre-vaccina-
tion period was defined as 1 January 2002 to 31 March 
2007, i.e. the time before the 7-valent introduction of 
the pneumococcal vaccine was assumed to start having 
an effect. We considered that an effect of the introduc-
tion of the 7-valent pneumococcal vaccine could first be 
seen from 1 April 2007, as we anticipated that all four 
doses of the vaccine, including the booster dose, would 
have been administered and had an effect within a year 
after birth. The end of the period to assess the effect of 
the 7-valent vaccine was 30 April 2011, i.e. before the 
10-valent vaccine replaced the 7-valent vaccine.
To study any additional effect of the introduction of the 
10-valent pneumococcal vaccine, the end of the study 
period was set to 31 December 2013. We considered 
that an effect of the introduction of the 10-valent vac-
cine could first be seen from 1 March 2012, assuming 
that the full vaccination schedule would have been 
administered within a year after birth. The end of the 
study was 31 December 2013.
We assessed the effect of the 10-valent vaccine in two 
ways. We first ran the model including the introduction 
of both vaccines. Secondly, we assessed the effective-
ness of the introduction of the 10-valent vaccination 
campaign as compared to pre-vaccination period, when 
data points following introduction of the 7-valent vac-
cine (1 June 2006 to 29 February 2012) were excluded.
Children born between 1 April 2006 and 28 February 
2011 were assumed to have received the 7-valent vac-
cine; children born before 1 April 2006 were assumed 
to have not been vaccinated, but potentially indi-
rectly protected by vaccination of younger age groups. 
Children born after 1 March 2011 were assumed to have 
received the 10-valent pneumococcal vaccine.
Statistical analysis
We first assessed the aggregated yearly respiratory 
antibiotic prescription proportions from 2002 to 2013 
for each age group separately by plotting the data. We 
then assessed monthly antibiotic prescription propor-
tions data using multiplicative decomposition [13] that 
shows the observed trend of the outcome as well as 
seasonal and random patterns, and the trend after 
removing the seasonal and random components.
To assess the effectiveness of the introduction of the 
pneumococcal vaccines, we used seasonal autoregres-
sive integrated moving average (SARIMA(p,d,q)(P,D,Q)s) 
time series models [14] with intervention analysis 
[15], where p and P is the number of auto-regressive 
components, d and D stands for differencing applied 
in the series, q and Q indicates the number of moving 
average components, and s is equal to the number of 
units of seasonal periods that are used in the model 
to remove additive seasonal effects. SARIMA allows us 
to estimate the effect of an intervention of interest by 
taking into account seasonal patterns. As pneumococ-
cal illness tends to occur during the winter months, we 
assumed seasonal patterns occurring every 12 months, 
and therefore s was set to 12. We estimated the level 
(the abrupt change) of respiratory antibiotic prescrip-
tion proportions and the change in trend (the slope) 
after, as compared with before, the introduction of the 
pneumococcal vaccines. The intervention variables 
were coded as 0 before the intervention and1 after 
the intervention. To assess the change in trends after 
the interventions were introduced, slope change vari-
ables denoting time were introduced. It was coded as 
0 before the interventions, and afterwards counted the 
number of months after the introduction of the inter-
vention of interest [16,17].
The best SARIMA models were identified based on the 
Akaike Information Criterion (AIC) during the pre-vacci-
nation period for each age group separately [18]. They 
were then applied to estimate the effects of the intro-
duction of the7- and 10-valent vaccines throughout each 
part of the study period, as described above. When both 
interventions were included in the same model, the 
best model (the model with only the first intervention 
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(introduction of the 7-valent vaccine) versus the model 
with both interventions) were selected based on a like-
lihood ratio test. The coefficients and their standard 
errors were estimated using maximum likelihood esti-
mation. The percentage of change and its confidence 
intervals were calculated as (exp(coefficient)−1)×100% 
and (exp(coefficient+/−1.96 ×standard error)−1)×100%.
The adequacy of each model was verified by visually 
assessing the correlograms (there should be negligible 
residual autocorrelation) and the plots of the residu-
als (the residuals of the model should be randomly 
scattered). The analysis was performed with RStudio 
0.97.551 statistical software [19].
Results
Aggregated yearly estimates revealed that very young 
children had the most prescriptions of respiratory anti-
biotics: this decreased with age (Figure). We observed 
a slight decrease in respiratory antibiotic prescriptions 
after the introduction of the pneumococcal vaccines in 
2006 and 2011 (Figure).We observed similar patterns 
when we inspected decomposed monthly trends of 
antibiotic prescriptions (data not shown).
To reveal the effects of the introduction of the pneu-
mococcal vaccines on respiratory antibiotic prescrip-
tions, we performed a time series analysis from 2002 
to 2013. The best time series SARIMA models were 
identified based on AIC during the pre-vaccination 
period (see Table 1for the best model for each age 
group) and the likelihood ratio test when the additional 
effect of the introduction of the 10-valent vaccine was 
assessed in the model, including both interventions at 
the same time. The final models did not show evidence 
of autocorrelation and we could not detect clear pat-
terns in the residual autocorrelation for most of the age 
groups. Only the models for the eight and nine year-old 
children showed significant autocorrelation at lag 12, 
indicating a remaining seasonal effect. However, due 
to low levels of autocorrelation, it is unlikely that this 
would have had a strong effect on the overall results.
The level of respiratory antibiotic prescription propor-
tions decreased after the introduction of the 7-valent 
vaccine in most of the age groups (Table 1). The reduc-
tion was, however, only statistically significant in three 
and four year-old children, −4.94% (95% CI: −5.26 
to −4.63) and −9.02% (95% CI: −14.82 to −2.83), 
respectively.
When we performed a likelihood ratio test, the model 
including both interventions was better than the model 
including the 7-valent vaccine intervention alone for a 
few age groups, namely in one, five and six year-olds. 
Figure 
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a Number of users per year/number of children in the particular age group in that year.
The children’s ages shown are the age at which the antibiotic was prescribed.
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However, estimates of the effect of the introduction 
of the 10-valent vaccine were inconsistent: the pro-
portions of antibiotic prescriptions decreased and/or 
increased after the introduction of 7- and/or 10-valent 
vaccination and the results were not statistically sig-
nificant (Table 2).
When we assessed the effectiveness of the introduc-
tion of the 10-valent vaccine as compared with the 
pre-vaccination period, we observed a reduction in res-
piratory antibiotic prescriptions of −13.04% (95% CI: 
−22.23 to −2.76), −20.31% (95% CI: −26.58 to −13.50), 
−16.92% (95% CI: −28.80 to −3.07), −22.34% (95% CI: 
−37.35 to −3.73), −23.75% (95% CI: −40.44 to −2.37) in 
two, three, four, six and seven year-olds, respectively 
(Table 3).
The trends of antibiotic prescription proportions were 
similar before and after the interventions in most age 
groups (Tables 1–3).
Discussion
We found a decrease in antibiotic prescriptions for res-
piratory infections in three and four year-old children 
after the introduction of the 7-valent pneumococcal vac-
cine. Furthermore, we demonstrated that the introduc-
tion of the 10-valent pneumococcal vaccine continued 
to add benefit in terms of fewer respiratory antibiotic 
prescriptions. It is important to note, however, that the 
effect estimates of the latter intervention most likely 
include the effects of the 7-valent vaccinations as well 
as herd immunity, as in our study, only children aged 
one and two years born after 1 March 2011 received the 
10-valent vaccine.
Our results are in line with the results from a recently 
conducted study on the effect of a 13-valent pneumo-
coccal conjugate vaccine on admissions to hospital in 
the US: in children up to five years-old, introduction 
of the vaccine led to the reduction of all-cause, inva-
sive pneumococcal and non-invasive pneumococcal or 
lobar pneumonia hospitalisation [20]. Such a decrease 
in outcomes, measured only a couple of years after 
Table 1 
Effectiveness of introduction of 7-valent pneumococcal vaccine by age: change in level of respiratory antibiotic prescriptions 
and in trend of respiratory antibiotic prescription proportions, the Netherlands, 2002–13
Children’s age 
in years
Change in level 
Percentage (95% CI)




1 1.20 (−3.51 to 6.13) 0.01 (−0.13 to 0.15) (6,0,5)(8,1,9)12
2 2.55 (−1.85 to 7.15) −0.26 (−0.42 to −0.10) (8,0,8)(5,0,5)12
3 −4.94 (−5.26 to −4.63) −0.16 (NA)a (8,0,3)(7,0,7)12
4 −9.02 (−14.82 to −2.83) −0.11 (−0.33 to 0.11) (8,0,4)(4,1,3)12
5 −3.26 (−7.39 to 1.07) −0.28 (−0.47 to −0.08) (5,0,0)(9,0,9)12
6 −10.10 (−21.64 to 3.14) −0.11 (−0.56 to 0.34) (2,0,3)(6,1,8)12
7 −14.14 (−35.28 to 13.91) 0.15 (−0.75 to 1.06) (0,0,1)(8,1,8)12
8 −7.93 (−24.17 to 11.79) −0.23 (−0.85 to 0.40) (2,0,5)(3,1,0)12
9 −12.72 (−31.47 to 11.17) −0.20 (−1.11 to 0.72) (0,0,0)(8,1,9)12
CI: confidence interval; NA: not applicable; SARIMA(p,d,q)(P,D,Q)s: seasonal autoregressive integrated moving average model with 
intervention analysis, where p and P is the number of auto-regressive components, d and D stands for differencing applied in the series, q and 
Q indicates the number of moving average components and s is equal to the number of units of seasonal period that are used in the model.
a The standard error could not be approximated using the maximum likelihood algorithm. 
Table 2
Added effectiveness of introduction of 10-valent pneumococcal vaccine for different agesa: change in level and trend of 
antibiotic prescription proportions, the Netherlands, 2002–13
Children’s age 
in years









1 5.54 (2.74 to 8.41) −0.13 (−0.21 to −0.05) −6.27 (−17.57 to 6.56) −0.63 (−1.52 to 0.27)
5 2.72 (−3.92 to 9.82) −0.29 (−0.50 to −0.07) 1.35 (−16.03 to 22.33) 0.32 (−0.87 to 1.53)
6 −10.32 (−21.03 to 1.85) −0.08 (−0.41 to 0.25) −0.08 (−0.41 to 0.25) −9.72 (−28.15 to 13.44)
CI: confidence interval.
a Included are only the ages for which an added effect of the introduction of the 10-valent vaccine was demonstrated, based on a likelihood 
ratio test.
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introduction of the new vaccine covering more sero-
types and with vaccination coverage in children up to 
five years-old of 54%in the US study indicates not only 
direct, but also indirect protection. We also found that, 
although it was not statistically significant, there was 
an indication of a decrease in prescriptions of respira-
tory antibiotics in unvaccinated children aged eight 
and nine years  born before the introduction of pneu-
mococcal vaccination.
Our point estimates of the effect of the introduction of 
the pneumococcal vaccines showed a decrease, but it 
was not always statistically significant. Even though 
overall antibiotic prescription trends had a decreasing 
pattern, after the introduction of the vaccines, there 
were some fluctuations. The effects of the pneumo-
coccal vaccines might therefore have been not signifi-
cant due to quite low overall use of antibiotics in the 
Netherlands [1,21], thus making the data more sensi-
tive to fluctuations. Moreover, it has been documented 
that after the introduction of the 7-valent pneumococcal 
vaccine in the Netherlands, invasive pneumococcal dis-
ease rates caused by non-vaccine serotypes increased 
[6,7]. This might also partly explain the observed fluc-
tuations, even after the introduction of the vaccines. 
However, in our study, we were unable to explore the 
effect of serotype replacement, since serotype-specific 
clinical outcome data were not part of the dataset.
We may not have been able to show the benefits of the 
10-valent pneumococcal vaccination in addition to the 
7-valent campaign due to several reasons. First, the 
10-valent vaccine covers additional three serotypes, 
meaning that the relative benefit of this campaign 
might be too small to detect when compared with the 
7-valent vaccine. Additionally, as mentioned above, 
we observed some fluctuation (small increases and 
decreases) in the data following the introduction of the 
vaccines. These factors might explain why there was no 
statistically significant added benefit of the 10-valent 
vaccine and that for several ages, the model including 
the 7-valent vaccine alone appeared to be better than 
the model including both campaigns. These explana-
tions seem plausible because when we assessed the 
effect of the 10-valent vaccine as compared with the 
pre-vaccination period, the observed reduction in res-
piratory antibiotic prescription proportions was large, 
reaching for some ages above 20%.
Because the pneumococcal vaccines targeted well-
defined population groups at the national level at 
well-defined time points and vaccination uptake rates 
were high (94–95%) [3,8], we were able to study the 
effects of the interventions at the population rather 
than individual level. This is advantageous as large 
population-based databases, such as IADB.nl, which 
do not include individual vaccination information, can 
still be used to assess the impact of population-based 
interventions. By using SARIMA time-series models, 
we were able to estimate direct (among children age 
done to seven years) and indirect (among eight to nine 
year-olds) effects of the introduction of the pneumo-
coccal vaccines. We were able to take seasonal effects 
into account as well as assess the introduction of both 
the 7-valent and 10-valent pneumococcal vaccinations 
by using different approaches.
Although we did not have information about the rea-
son for the antibiotic prescriptions, the antibiotics that 
we looked at are specifically recommended to treat 
acute otitis media and pneumonia in young children in 
the Netherlands [9,10]. As S. pneumoniae is one of the 
leading causes of mucosal infections [22], our results 
are likely to indicate an effect of the introduction of the 
pneumococcal vaccines on health problems caused by 
S. pneumoniae.
Table 3
Effectiveness of introduction of 10-valent pneumococcal vaccine for children aged one to nine years: change in level and 







1 0.22 (−8.92 to 10.28) −1.43 (−2.16 to −0.69)
2 −13.04 (−22.23 to −2.76) −0.80 (−1.69 to 0.10)
3 −20.31 (−26.58 to −13.50) −0.04 (−0.94 to 0.87)
4 −16.92 (−28.80 to −3.07) −0.66 (−1.70 to 0.40)
5 −11.94 (−24.26 to 2.38) −0.47 (−1.73 to 0.81)
6 −22.34 (−37.35 to −3.73) −0.56 (−2.14 to 1.05)
7 −23.75 (−40.44 to −2.37) −0.51 (−2.29 to 1.30)
8 −15.11 (−41.20 to 22.57) −1.75 (−3.81 to 0.35)
9 −29.29 (−51.52 to 3.14) −0.63 (−2.94 to 1.74)
CI: confidence interval.
a Pre-vaccination period: 1 January 2002 to 31 May 2006.
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In conclusion, our study provides evidence that intro-
duction of the 7- and 10-valent pneumococcal vaccines 
were effective in reducing respiratory antibiotic pre-
scriptions in young children, with a reduction of about 
5–24% in antibiotic prescriptions for mucosal infec-
tions likely due to the introduction of the pneumococ-
cal vaccines. Nevertheless, it is important to keep in 
mind that due to its recent introduction, the effect of 
the introduction of the 10-valent vaccine is likely in 
part due to the continuing effects of the 7-valent vac-
cine and herd immunity. Future studies are needed to 
further assess the effects of the pneumococcal vac-
cines on different health outcomes as well on popula-
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